Reversine is a cell-permeable, selective and ATP-competitive inhibitor of human A3 adenosine receptor and a pan-aurora A/B/C kinase inhibitor as well with potential anticancer activity.

Piclidenoson, formerly known as CF101, is a specific agonist to the A3 adenosine receptor, which inhibits the development of colon carcinoma growth in cell cultures and xenograft murine models.

XAC is novel and potent adenosine receptor antagonist.

Namodenoson (2-Cl-IB-MECA; CF102; CF-102) is a novel, potent, orally bioavailable, and highly selective adenosine A3 receptor (A3AR) agonist with potential anticancer activity.

SR 59230A HCl is a potent, brain penetrant and selective β3 adrenoceptor antagonist with IC50 values of 40, 408 and 648 nM for β3, β1 and β2 receptors respectively.

MRS1754 (MRS-1754; MRS 1754) is a novel, selective and potent A2B antagonist 2B antagonist with anticancer activity.

Tozadenant (formerly RO-4494351; SYN-115) is an orally bioavailable, selective adenosine A2A receptor antagonist with potential usefulness in the treatment of Parkinson disease (PD).

Nicergoline tartrate is a naturally occuring ergot derivative and a vasoactive drug with α-adrenergic blocking activity, producing vasodilatation.